sector medic suppli devic
 sinuva hit anoth snag ceo
transit could limit downsid lower pt
elicit yet anoth revamp sputter launch effort reduct
sale guidanc expect disappoint updat least partial
overshadow announc ceo transit believ provid
opportun bod evalu strateg option wrote back februari
see view logic takeout candid qualiti could limit near-
term downsid stock lower pt maintain
anoth fals start sinuva first quarter sale came slightli
consensu howev sinuva contribut revenu
intersect continu struggl sort market access issu
back result manag lower full year sale guidanc
impli growth yoy see disappoint updat
especi sinc almost month remov sinuva fda approv
yet second time sinc launch product intersect revamp go-to-market
strategi dedic in-hous resourc shepherd physician offic staff
reimburs process believ remain gate factor adopt
compani still work solv basic market access issu stage
inexcus view perplex given fact
progress metric manag provid appear move right direct
exampl total sinuva custom overal purchas
product via buy-and-bil today end
buy-and-bil pathway manag point throughout bottleneck
system yet despit compani suffici evid demonstr wari
physician get paid averag rate cover cost product plu
reason mark-up volum ramp remain elus manag believ due
prior author process still hassl worth ent
earn staff focu schedul surgeri go back forth
payer sinuva patient intersect provid assist front go
forward dedic reimburs field rep goal reduc friction
point aggress adopt make sens physician dedic j-code
sinuva recommend preliminari rule last week could go
effect januari also help yet multipl fals start expect investor
take show approach sinuva statu potenti growth driver
ceo transit provid opportun assess option latest revamp
sinuva launch take place backdrop leadership transit
longtim ceo lisa earnhardt step becom head abbott medic
devic busi board search perman replac chairman
kieran gallahu step serv interim ceo start june investor
familiar mr gallahu prior stint run carefus latter
end sale believ mr gallahu presenc
leav compani good hand search process declin
comment monday call whether would consid take perman
think outcom would well receiv street anoth attract candid
turn meantim transit could provid opportun board
evalu strateg option busi well written previous view
intersect attract takeout candid portfolio would fit neatli
larg ent competitor continu see potenti signific valu
creation stand-alone basi given compani recent execut issu think
page analyst certif import disclosur
fair question whether valu could better realiz umbrella larger
experienc player
turn back quarter believ sinuva distract continu cast
shadow intersect base busi well first quarter propel/contour sale grew
modestli ahead consensu forecast impli
growth unit basi mid-single-digit run rate seen
disappoint result consid fact manag put addit resourc place
back august tri better insul base busi distract sinuva
reimburs troubleshoot previous anticip reacceler
propel sale begin comp eas rein assumpt account
on-going disrupt model call intersect gener overal revenu
propel/contour sale sinuva contribut
anoth compar prior forecast call total revenu
includ base busi sinuva
incom statement stronger expect gross margin off-set
increas opex intersect report gross margin yoy
consensu meanwhil sg expens rose yoy sale
street forecast final spend rose revenu
consensu combin drove net loss per share
compar street forecast per share loss full year
manag continu expect gross margin come vs
oper expens still forecast despit reduc top line outlook
increas spend reimburs support increment stock-bas compens
relat ceo transit off-set save elsewher
pipelin front ascend readout later year remain potenti catalyst
intersect expect ascend trial evalu novel drug-coat balloon sinuplasti
system complet enrol headlin result possibl yearend posit
data could posit compani take meaning share balloon sinuplasti
market revenu would wholli increment current forecast given fact
model current give intersect credit new balloon offer remain
seen whether ascend alon suffici support fda approv whether
anoth studi could requir assum trial enough estim intersect
could receiv approv late earli
bounc back longer tap lower pt come year
view intersect strong candid bounc back disappoint
build momentum comp eas sinuva gain traction instead increasingli
look like anoth lost year compani posit check sinuva clinic
perform continu lead us believ opportun product real
expect long-term growth potenti fulli reflect stock
compani begin demonstr improv execut also see near-term downsid
somewhat limit due option offer ceo transit lower
price target reflect revis estim signific
upsid potenti price target current level maintain buy rate
page analyst certif import disclosur
intersect develop drug/devic combin product treatment chronic sinus
compani propel implant dramat improv outcom fess patient
reduc complic need revis procedur market opportun
 alon intersect achiev solid traction propel sinc launch
introduct contour version product design specif
peripher sinus help drive penetr fess
procedur see ampl runway propel/contour go forward
expect investor focu shift intersect sinuva implant patient recurr
symptom follow sinu surgeri see sinuva increment opportun
potenti provid difficult patient popul minimally-invas
altern revis surgeri someth check indic repres signific
unmet clinic need driven continu penetr base product portfolio earli
adopt sinuva estim intersect grow revenu roughli compound-annual-growth-rate
next four year combin gross margin strong balanc sheet
path profit believ outlook stack well best growth
stori med-tech
valu intersect ent primarili ev/sal basi use repres group
small-cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade
ntm sale vs intersect multipl lower price target
base multipl forward ntm sale estim
signific upsid potenti target current level assign intersect ent
downsid risk rate price target includ commerci payer reduc
reimburs fess procedur propel adopt fall short street
expect sinuva launch fall short street expect
becton dickinson compani nc
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
